View Post

North Carolina Vaccine Facility Certified for the Next Pandemic

In Influenza Vaccine News by Influenza Vaccine

If the U.S. government declares an influenza pandemic, a new vaccine production facility located in Holly Springs, North Carolina, is certified and ready to go.
New Jersey-based Seqirus announced today that the company's innovative manufacturing facility has successfully achieved all criteria required to establish domestic manufacturing capability for cell-based seasonal and pandemic influenza vaccines as outlined by the Biomedical Advanced Research and Development Authority (BARDA).

View Post

COVID-19 Confirmed More Costly and Fatal than Influenza

In Influenza Vaccine News by Influenza Vaccine

According to a recent retrospective cohort study conducted at the Hospital del Mar in Barcelona, Spain, when adults were hospitalized with COVID-19, they were at a greater risk of death than those with influenza.
After accounting for potential confounders, including age, comorbidities, sex, disease severity, pneumonia, and corticosteroid treatment, these researchers found that COVID-19 patients were more than three times as likely to die after being admitted to hospital than influenza patients.

View Post

Self-Amplifying Messenger RNA Transforms Common Flu Shots

In Influenza Vaccine News by Influenza Vaccine

A global leader in influenza prevention recently announced a significant investment in a new Research and Development (R&D) facility located in Waltham, Mass. 
Seqirus, a business of CSL Limited, confirmed on February 7, 2022, the new facility will support the company’s growing R&D portfolio, focusing on a self-amplifying messenger RNA (sa-mRNA) technology platform, the next generation of mRNA technology. 

View Post

Influenza Vaccination Failed to Reduce COVID-19 Risk

In Influenza Vaccine News by Influenza Vaccine

In a new study from the University of Copenhagen, vaccination against influenza was found to not change the risk of hospitalization or symptoms due to COVID-19.
And influenza vaccination was not associated with the risk of contracting SARS-CoV-2 infection as assessed by the presence of antibodies against SARS-CoV-2. 
This study focused on the working population and subgroup analyses of outcomes related to the severity of disease included a sparse number of HCW aged ≥65 who had contracted SARS-CoV-2.

View Post

Reduced Flu Shot Rates Raise Concerns at the U.S. CDC

In Influenza Vaccine News by Influenza Vaccine

The US Centers for Disease Control and Prevention (CDC) announced initial estimates for influenza vaccine uptake among children and pregnant women for the 2021-2020 flu season are lower compared to the same time last season.
The reported 15% point drop in influenza vaccination coverage among pregnant women and a 6% decrease in children could put many people at risk this flu season. 
The CDC stated on October 27, 2021, this trend ‘could be dangerous for many of the people in these groups who may be at higher risk of developing serious influenza complications.’

View Post

Novel Influenza A Virus Confirmed in the U.S.

In Influenza Vaccine News by Influenza Vaccine

The US Centers for Disease Control and Prevention (CDC) reported two previous human infections with novel influenza A viruses.
One infection with an influenza A(H1N1) variant (A(H1N1)v) virus was reported by North Dakota that occurred during the 2020-21 influenza season.
And one infection with influenza (A(H3N2)v) virus was reported by Ohio that occurred during the current 2021-22 influenza season. 
Both patients are younger than 18 years of age, were not hospitalized, and have recovered or are recovering from their illness. 

View Post

Updated Recommendations for the Prevention and Control of Influenza in Children

In Influenza Vaccine News by Influenza Vaccine

The American Academy of Pediatrics (AAP) announced recommendations for the routine use of influenza vaccine and antiviral medications to prevent and treat influenza in children during the 2021–2022 influenza season. 
The AAP stated on September 7, 2021, it recommends annual influenza immunization of all children without medical contraindications, starting at six months of age.
Excerpts from the AAP statement are discussed below:

View Post

Flu Vaccine Candidate Demonstrated Multi-Seasonal, Seven-Year Drifted Influenza Strain Protection

In Influenza Vaccine News by Influenza Vaccine

Influenza H3N2 virus continues to be a major cause of morbidity and mortality, especially for the older age groups, stated researchers in a new study published by The Journal of Infectious Diseases.
Although seasonal influenza vaccines are evaluated annually for the need to update the immunization with antigenically contemporary strains, H3N2 vaccine efficacy (VE) with currently licensed vaccines continues to be lower than for H1N1 or B viruses.